Maureen A. Su find the epigenetic regulator UTX complexes with transcription factors TCF1 and STAT3 to promote pathogenicity of long-lived, stem-like progenitor T cells in models of type 1 diabetes (T1D)
1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.
2Department of Pediatrics and.
3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Sunny Y. Wong & team characterize gene expression changes that occur during acne pathogenesis and identify a therapeutic that reduces acne-like pustule formation in a mouse model of high fat diet-induced folliculitis:
The image shows prominent neutrophilic pustules from ear skin of the mouse model, stained for the neutrophil marker Ly6G (green) and KRT14 (red).
Address correspondence to: Sunny Y. Wong or Joseph S. Durgin, Department of Dermatology, University of Michigan, 1,500 E. Medical Center Dr., Ann Arbor, Michigan 48,109, USA. Email: [email protected] (SYW); [email protected] (JSD).
The expert council of the Japanese Ministry of Health has approved two regenerative medicine drugs based on induced pluripotent stem cells (iPSCs) — a cure for Parkinson’s disease and heart failure. If the health minister approves the experts’ decision, Japan will become the first country in the world to allow the commercial sale of such products — almost 20 years after the discovery of the technology itself.
Japan’s health ministry said on Thursday a panel of specialists had endorsed Sumitomo Pharma’s iPS cell-derived treatment for Parkinson’s disease, paving the way for the world’s first medical products based on the technology.
A new electronic implant system can help lab-grown pancreatic cells mature and function properly, potentially providing a basis for novel, cell-based therapies for diabetes. The approach, developed by researchers at the Perelman School of Medicine at the University of Pennsylvania and the School of Engineering and Applied Sciences at Harvard University, incorporates an ultrathin mesh of conductive wires into growing pancreatic tissue, according to a study published in Science.
“The words ‘bionic,’ ‘cybernetic,’ ‘cyborg,’ all of those apply to the device we’ve created,” said Juan Alvarez, Ph.D., an assistant professor of Cell and Developmental Biology. While these terms may sound futuristic, he noted this approach is already in use in the form of deep brain stimulation, which treats neurological conditions.
“What we’re doing is like deep stimulation for the pancreas. Just like pacemakers help the heart keep rhythm, controlled electrical pulses can help pancreatic cells develop and function the way they’re supposed to,” he said.
Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have been repeatedly exposed to viruses throughout their careers, causing them to build up an immune system capable of defending against an array of pathogens.
The respiratory syncytial virus (RSV) causes mild cold-like symptoms in healthy adults, but is the leading cause of lower respiratory tract infections in children, accounting for 30–50% of hospitalizations. The human metapneumovirus (hMPV) is the second most common cause of lower respiratory tract infections in children, accounting for 6–15% of hospitalizations. Both are also major causes of severe respiratory infections in older adults and immunocompromised people.
While RSV vaccines exist, they are currently only approved for older adults, as pediatric vaccines have faced safety challenges associated with enhanced respiratory disease risks. Vaccination before immune-ablative therapies in immunocompromised individuals has also been shown to be ineffective. Meanwhile, there are currently no approved therapies or prophylactics for hMPV.
Prostate cancer often develops very slowly. For the vast majority, this is a disease that you live well with, without the need for treatment, but some get an aggressive variant with recurrence of cancer even after surgery. The disease behaves very differently from patient to patient. Understanding what makes the cancer aggressive is crucial for better diagnostics and treatment, says the author.
Aggressive cancer has its own gene expression: The researchers identified a pattern in the gene expression of the tumor itself in prostate tissue in patients with a high risk of recurrence and spread. This signature can become a new tool for distinguishing between patients who need intensive care and those who can manage with less intensive follow-up.
Inflammation of apparently healthy tissue: Signs of inflammation and changes in metabolic processes were also found in the normal tissue close to the cancerous tumor. These glands had high activity of neurotransmitters that attract immune cells, and an increased occurrence of a cell type that can trigger inflammatory reactions. At the same time, the levels of important substances had decreased, suggesting that the gland had lost its normal function.
“Aggressive prostate cancer appears to be associated with inflammation in the area around the cancer cells, combined with specific genetic signatures and metabolic changes in the prostate tissue. This knowledge can provide better methods for early identification of patients at high risk,” says the author. ScienceMission sciencenewshighlights.
The research lays a foundation for the possibility that aggressive prostate cancer can probably be detected through a few drops of semen or blood in the long term.
Prostate cancer is the most common form of cancer among men in Western countries.